Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utidelone PK and DDI with Capecitabine in Breast Cancer
NCT05052437Phase 1Completed
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
- Start
- Oct 2020
- Primary completion
- Jan 2021
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, open-label trial of utidelone in breast cancer (2 arms), sponsored by Beijing Biostar Pharmaceuticals Co., Ltd. Primary endpoints: Peak Plasma Concentration at 12 weeks, Concentration-Time Curve at 12 weeks and 1 more. Started Oct 2020; status: completed.
02
Drugs
utidelone
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05052437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05052437.